R&D channel feed – Endpoints News

R&D channel feed

ScPharma's stock droops on 'deficiencies' as FDA tosses back heart failure drug application

8 years ago

Madrigal shares soar on promising PhII NASH data, stoking hopes for a new contender

8 years ago

Gilead and Galapagos bag promising PhII data for star immunology drug filgotinib — boosting late-stage focus

8 years ago

Following ASCO preview flop, Syndax bets on new combo deal with Nektar

8 years ago

FDA slaps a clinical hold on sickle cell IND filed for a new gene therapy from Vertex and CRISPR Therapeutics

8 years ago

PhRMA's new report counts each cancer drug in the US pipeline, which has now swelled to over 1,000 in the clinic

8 years ago

J&J hustles Legend’s promising BCMA CAR-T into PhI/II trial, winning an FDA green light to begin recruiting patients

8 years ago

FDA moves Sage’s postpartum depression drug brexanolone into regulators’ busy priority lane

8 years ago

AstraZeneca writes off its second pivotal COPD trial for Fasenra, killing expansion plans

8 years ago

Racing to grab market share in diabetes, Novo touts its oral semaglutide win over Jardiance in PhIIIa trial

8 years ago

Top research execs from Teva, Allergan recruited to help lead Axovant out of the R&D wasteland

8 years ago

Genmab takes a hit after J&J sounds retreat on cancer combos, as patient deaths force researches to scrap trials

8 years ago

Roche's Tecentriq scores again on a pivotal frontline lung cancer trial, positioning them against Merck, Bristol-Myers

8 years ago

After some stinging setbacks, a top analyst questions the high failure rate for Celgene's drug pipeline

8 years ago

AstraZeneca caps its big win in lung cancer with positive survival data for Imfinzi — and what a relief it is

8 years ago

AstraZeneca unveils its brand new open-office center in the Bay Area. Do you love it, or hate it?

8 years ago

Astellas shedding 600-plus jobs as CEO shakes up R&D and sales ops in restructuring

8 years ago

New PhIII gives Esperion's CEO a chance to push back against a legion of critics — but can he win back investors?

8 years ago

Merck crushes Keynote-407 study in frontline lung cancer, hitting co-primaries and setting up another quick OK

8 years ago

Cara hauls in $70M on first leg of global deal, setting up PhIII kidney disease drug for commercial roll out

8 years ago

Sesen's PhIII bladder cancer data send stock south as investors fret over safety

8 years ago

Allergan doubles down on NMDA depression drug development efforts, bagging an option to a small molecule followup drug

8 years ago

Buoyed by hemophilia A gene therapy update, BioMarin switches to head-to-head study -- but shares slide on durability concerns

8 years ago

Hunting a cure, Spark reports steady progress on hemophilia B gene therapy as Pfizer preps for pivotal handoff

8 years ago

First page Previous page 271 272 273274275 276 277 Next page Last page